10/10/2011
SYNOLIS V-A is an innovative, new-generation treatment for osteoarthritis. It addresses not only the mechanical background of the disease but also the underlying inflammatory processes. A unique combination of 2% Sodium Hyaluronate (NaHA) and 4% Sorbitol, SYNOLIS V-A addresses the limits of traditional viscosupplements, significantly reducing pain throughout the therapy.
- General information NaHA 20 mg/ml : biofermentative origin, pure product, molecular weight > 2.2 MDa in the sterilized product
- Sorbitol : 40 mg/ml
- Volume per syringe : 2 ml
- Sterilization mode : Steam sterilization
- Primary packaging : Glass syringe with ergonomic finger grip and rod
- Secondary packaging : Second sterility barrier, in boxes of 1 or 3 syringes
- Recommended clinical protocol : 1 intra-articular injection per week for 3 consecutive weeks
- Storage condition : Room temperature
Mission The aim of SYNOLIS V-A treatment is to :
• slow down inflammatory processes
• provide rapid pain relief
• improve joint mobility
